Mirum Pharmaceuticals, Inc. Common Stock MIRM
$98.22
-2.38%
at last close
Market Cap$6.53 billion
P/E Ratio—
Div Yield—
Volume441.1K
52-Week Range
$57.79$130.00
Analyst Ratings
- Consensus
- Buy — 13 Buy · 0 Hold · 0 Sell (13 analysts)
- Avg. Price Target
- $135.54 (+38.0% upside)
Key Stats
- Today's Range
- $97.80 – $103.28
- 50-Day Range
- $88.88 – $130.00
- 52-Week Range
- $57.79 – $130.00
- Volume
- 441K shs
- Average Volume
- 627K shs
- Market Cap
- $6.53 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- -626.83
- Price / Sales
- 10.57
Short Interest
- Short Interest
- 0.09%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $618.07 million
- Net Income
- $-860,207,000
- Net Margin
- -139.18%
- Return on Equity
- 8253.76%
- Debt-to-Equity
- —
About Mirum Pharmaceuticals, Inc. Common Stock
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Related Stocks
Compare head-to-head: MIRM vs LLY·MIRM vs JNJ·MIRM vs ABBV·MIRM vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.